Core Viewpoint - Walmart is expected to report strong fourth-quarter earnings, with revenue projected at $189.18 billion, an increase from $180.55 billion in the same quarter last year, and earnings per share anticipated to rise to 73 cents from 66 cents [2][3]. Earnings Estimates - Analysts predict Walmart's fourth-quarter revenue will be $189.18 billion, marking a year-over-year increase of approximately 4.5% [2]. - The expected earnings per share for the fourth quarter is 73 cents, up from 66 cents in the previous year [2]. Analyst Insights - Walmart has consistently exceeded revenue estimates for over 15 consecutive quarters and earnings estimates in seven of the last eight quarters [2][3]. - Market experts suggest that while Walmart's stock may perform well post-earnings, it may not sustain a rally due to high expectations already priced into the stock [4]. - Walmart's price-to-earnings ratio is noted to be 46, higher than most of the "Magnificent Seven" stocks, indicating a premium valuation [5]. CEO Transition - The upcoming earnings report will be the first under new CEO John Furner, with expectations of continued market share gains and stable comparable sales growth in the 4%-5% range [6]. Recent Performance - Walmart has shown consistent U.S. comparable sales growth in the range of 4.5%-4.8% over the last four quarters [7]. - The company's international sales have also seen a year-over-year increase of 10.8% [8]. Key Items to Watch - Investors are keen to see how consumer spending trends are reflected in the earnings report, particularly whether there is a shift from name-brand to private-label products [8]. - Strong growth in both U.S. and international segments, along with positive guidance for the next fiscal year, is anticipated to impact major stock market indexes and consumer staple ETFs significantly [9]. Stock Performance - As of the latest report, Walmart's stock is trading at $128.63, down 0.2%, with a year-to-date increase of 14.1% and a 52-week increase of 23.9% [11].

Core Viewpoint - QuantumScape is experiencing stock pressure due to a combination of financial performance, technical weaknesses, and market conditions. Financial Performance - QuantumScape reported a fourth-quarter loss of 17 cents per share, which was better than the expected loss of 18 cents per share [2] - The company highlighted capital expenditures totaling $36.3 million for the full year, with customer billings reaching $19.5 million in 2025 [2] Business Model - QuantumScape is focused on developing next-generation solid-state lithium-metal batteries for electric vehicles and other applications, offering greater energy density, faster charging, and enhanced safety [6] Market Position and Technical Analysis - The stock is trading 22.2% below its 20-day simple moving average (SMA) and 42.9% below its 100-day SMA, indicating significant short to medium-term weakness [4] - Shares have decreased 28.34% over the past 12 months and are closer to their 52-week lows than highs, suggesting a challenging market environment [4] - The RSI is at 29.69, indicating oversold territory, while the MACD shows bearish momentum with a value of -0.8096 [5] Customer Base and Partnerships - The company emphasizes its diverse customer base and robust partner ecosystem, believing it has a variety of customer and application opportunities [3] Momentum and Market Sentiment - QuantumScape's Benzinga Edge scorecard indicates strong momentum (Score: 69.62), suggesting positive price action relative to the broader market despite facing technical challenges [7] - At the time of publication, QuantumScape shares were down 0.56% at $7.15 [8]

In what could be described as a "Hail Mary" for a company currently treading water at penny-stock levels, Rackspace Technology, Inc. (NASDAQ:RXT) announced a strategic partnership Wednesday with data-giant Palantir Technologies, Inc. (NASDAQ:PLTR) . RXT stock is soaring. See the chart and price action here. The move, designed to accelerate the deployment of Palantir's Foundry and Artificial Intelligence Platform (AIP), sent Rackspace shares into a triple-digit rally. But beneath the AI-powered press release ...

In what could be described as a "Hail Mary" for a company currently treading water at penny-stock levels, Rackspace Technology, Inc. (NASDAQ:RXT) announced a strategic partnership Wednesday with data-giant Palantir Technologies, Inc. (NASDAQ:PLTR) . RXT stock is soaring. See the chart and price action here. The move, designed to accelerate the deployment of Palantir's Foundry and Artificial Intelligence Platform (AIP), sent Rackspace shares into a triple-digit rally. But beneath the AI-powered press release ...

Planet Labs PBC (NYSE:PL) shares are trading higher Wednesday morning, despite a lack of company-specific news for the session. The stock is moving higher a day after a new Schedule 13G/A filing revealed that Driehaus Capital Management owns 8.51 million Class A shares of Planet Labs, representing a 2.91% stake as of Dec. 31.Here’s what investors need to know.Planet Labs stock is surging to new heights today. Why is PL stock surging?13G Signals Institutional ConfidenceThe institutional investor reported sha ...

Core Insights - The European Commission has granted ImmunityBio authorization for its bladder cancer treatment ANKTIVA, allowing the company to expand its commercial presence across four regulatory jurisdictions in under two years since its initial FDA approval [1][2] - ImmunityBio's stock has experienced a significant increase of 123.73% over the past year, currently trading at $7.46, which is 18.6% above its 20-day simple moving average (SMA) and 159.3% above its 200-day SMA [3] - Analysts have a positive outlook on ImmunityBio, with a consensus Buy rating and an average price target of $11.80, reflecting strong earnings expectations and recent upward revisions in revenue estimates [6] Regulatory and Market Expansion - The authorization includes key markets such as the Kingdom of Saudi Arabia, where ANKTIVA has received approval for two indications, indicating its growing acceptance and potential market impact [1] - ImmunityBio is committed to long-term safety and efficacy follow-ups with trial participants, which is essential for maintaining authorization and possibly expanding indications [2] Stock Performance and Analyst Sentiment - The stock's recent performance shows a robust upward trend, supported by solid fundamentals, despite mixed technical indicators suggesting some bearish pressure [3][4] - Upcoming earnings report is anticipated on March 2, 2026, with analysts finalizing forecasts, indicating heightened investor interest [5] - Recent analyst actions include maintaining a Buy rating and adjusting price targets, with D. Boral Capital maintaining a target of $24.00 and HC Wainwright & Co. raising their target to $10.00 [6]

Core Viewpoint - Lennar's significant investment in Opendoor Technologies indicates confidence in the future of digital home sales and strengthens the strategic partnership between the two companies, positively impacting Opendoor's stock price [1][3]. Group 1: Company Overview - Lennar is one of the largest homebuilders in the U.S., focusing on single-family homes and offering mortgage, title, and insurance services, making it a key indicator of housing demand [2]. - Opendoor Technologies is experiencing strong stock performance, with a notable increase in share price attributed to investor optimism and strategic partnerships [1][8]. Group 2: Financial Performance and Expectations - Opendoor is set to report earnings, with expectations of a loss of approximately $0.10 per share and quarterly revenue around $595 million; any improvement in losses or growth in builder channels could further boost the stock [4]. - Over the past year, Opendoor's shares have surged by 202.49%, indicating a strong recovery and positioning closer to 52-week highs [5]. Group 3: Technical Analysis - The stock is currently trading 12.4% below its 20-day simple moving average (SMA) and 31.8% below its 100-day SMA, suggesting short-term weakness, while being 0.2% above its 200-day SMA, indicating a potential long-term bullish outlook [5][6]. - The Relative Strength Index (RSI) is at 31.41, showing neutral momentum, while the MACD indicates bearish pressure, reflecting mixed momentum and uncertainty in the stock's near-term direction [6]. Group 4: Market Sentiment - The Benzinga Edge scorecard rates Opendoor Technologies with a strong momentum score of 96.54, indicating it is outperforming the broader market; however, profitability challenges remain a concern for sustaining investor confidence [7].

Core Viewpoint - Boeing's stock remains stable as investors assess the implications of the FTC's consent order regarding its acquisition of Spirit AeroSystems and Air Astana's recent order for 15 Boeing 787-9 Dreamliners [1] Group 1: FTC Consent Order - The Federal Trade Commission (FTC) has finalized conditions for Boeing's acquisition of Spirit AeroSystems, addressing antitrust concerns [1][2] - The order requires Boeing to divest certain Spirit operations while ensuring support services for competing aerospace manufacturers [3] - The FTC's ruling aims to prevent restrictions on Airbus's access to critical aerostructure components and to maintain fair pricing and innovation in the aviation supply chain [4] Group 2: Air Astana Order - Air Astana has finalized an order for up to 15 Boeing 787-9 Dreamliners, marking its largest single aircraft purchase to modernize its fleet [5] - This order, initially disclosed as a commitment in November 2025, will increase Air Astana's Dreamliner fleet to as many as 18 aircraft to support long-haul growth [5] Group 3: Stock Performance - Boeing shares were down 0.71% at $242.31, nearing a 52-week high of $254.34 [6]

Core Insights - Tempus AI has introduced its new HRD-RNA algorithm, an AI-driven tool aimed at enhancing the detection of homologous recombination deficiency (HRD) in tumors, which has positively impacted its stock price [1][6] Product Development - The HRD-RNA algorithm analyzes gene expression to identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, providing a more dynamic assessment of tumor biology compared to traditional genomic methods [2] - A real-world validation study indicated that HRD-RNA–positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens experienced a significant reduction in mortality risk compared to those receiving non-platinum therapies [2] - The company plans to make the HRD-RNA test clinically available later this year, offering physicians a functional view of HRD status by examining the transcriptome [3] Technical Analysis - The stock is currently trading 8.3% below its 20-day simple moving average (SMA) and 25.8% below its 100-day SMA, indicating a bearish trend [4] - Over the past 12 months, shares have decreased by 35.86%, positioning them closer to their 52-week lows [4] - The RSI is at 35.53, indicating neutral territory, while the MACD shows a value of -3.9401, below its signal line, suggesting bearish pressure [4][5] Analyst Outlook - Tempus AI is set to report earnings on February 24, 2026, with an EPS estimate of a loss of 13 cents, improved from a loss of 18 cents year-over-year [7][10] - Revenue estimates stand at $364.25 million, up from $200.68 million year-over-year [10] - The stock carries a Buy Rating with an average price target of $76.60, although recent analyst actions indicate mixed sentiments with some lowering their targets [8][10] Market Position - The company is positioned as a leader in precision medicine, leveraging AI to enhance treatment options and potentially improve patient outcomes [6] - Key resistance for the stock is identified at $61.50, while key support is at $50.00 [9] - Tempus AI shares were up 3.41% at $54.35 during premarket trading, reflecting some positive market activity [11]

Financial giants have made a conspicuous bullish move on Cameco. Our analysis of options history for Cameco (NYSE:CCJ) revealed 9 unusual trades.Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $337,126, and 7 were calls, valued at $363,843.Expected Price MovementsBased on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $ ...